NDC Package 10122-141-02 Retavase

Reteplase Kit - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
10122-141-02
Package Description:
1 KIT in 1 BOX * 10 mL in 1 VIAL, SINGLE-USE * 10 mL in 1 SYRINGE (10122-142-01)
Product Code:
Proprietary Name:
Retavase
Non-Proprietary Name:
Reteplase
Usage Information:
RETAVASE is indicated for use in acute ST-elevation myocardial infarction (STEMI) to reduce the risk of death and heart failure. Limitation of Use: The risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose STEMI puts them at low risk for death or heart failure.
11-Digit NDC Billing Format:
10122014102
Billing Unit:
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
NDC to RxNorm Crosswalk:
  • RxCUI: 763138 - reteplase 10 UNT Injection
  • RxCUI: 763141 - Retavase 10 UNT Injection
  • RxCUI: 763141 - reteplase 10 UNT Injection [Retavase]
  • Product Type:
    Human Prescription Drug
    Labeler Name:
    Chiesi Usa, Inc.
    Dosage Form:
    Kit - A packaged collection of related material.
    Sample Package:
    No
    FDA Application Number:
    BLA103786
    Marketing Category:
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date:
    10-30-1996
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    NDC HCPCS Crosswalk

    This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

    NDC 10122-141-02 HCPCS crosswalk information with package details and bill units information.

    NDC Billing CodeHCPCS CodeHCPCS Code Desc.DosagePackage SizePackage QuantityBillable UnitsBillable Units / Pkg
    10122014102J2993Reteplase injection18.1 MG1212

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 10122-141-02?

    The NDC Packaged Code 10122-141-02 is assigned to a package of 1 kit in 1 box * 10 ml in 1 vial, single-use * 10 ml in 1 syringe (10122-142-01) of Retavase, a human prescription drug labeled by Chiesi Usa, Inc.. The product's dosage form is kit and is administered via form.

    Is NDC 10122-141 included in the NDC Directory?

    Yes, Retavase with product code 10122-141 is active and included in the NDC Directory. The product was first marketed by Chiesi Usa, Inc. on October 30, 1996 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 10122-141-02?

    The contents of this package are billed per "each", products billed on a per each basis are usually products dispensed in discreet units.

    What is the 11-digit format for NDC 10122-141-02?

    The 11-digit format is 10122014102. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-210122-141-025-4-210122-0141-02